Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Imaging for precision medicine : can V-P SPECT measure mepolizumab response in asthma?

McDonald, Vanessa M. ; Urroz, Paola D. ; Bajc, Marika LU ; Rutherford, Natalie ; Brooker, Bree and Gibson, Peter G. (2021) In Respirology Case Reports 9(3).
Abstract

Monoclonal antibody therapies are effective for many but not all people with severe asthma. Precision medicine guides treatment selection using biomarkers to select patients most likely to respond according to their inflammatory endotypes. However, when assessing response to treatment, greater precision is required. We report a case series describing treatment response to mepolizumab in four severe asthma patients, assessed by traditional methods and with objective ventilation/perfusion single photon emission computed tomography (V-P SPECT). In this series, patients with severe asthma received mepolizumab treatment with clinical outcomes recorded at commencement and at approximately 16 weeks post-treatment initiation. V-P SPECT imaging... (More)

Monoclonal antibody therapies are effective for many but not all people with severe asthma. Precision medicine guides treatment selection using biomarkers to select patients most likely to respond according to their inflammatory endotypes. However, when assessing response to treatment, greater precision is required. We report a case series describing treatment response to mepolizumab in four severe asthma patients, assessed by traditional methods and with objective ventilation/perfusion single photon emission computed tomography (V-P SPECT). In this series, patients with severe asthma received mepolizumab treatment with clinical outcomes recorded at commencement and at approximately 16 weeks post-treatment initiation. V-P SPECT imaging was performed before and after treatment to determine ventilation heterogeneity and perfusion, and its ability to assess treatment responsiveness. V-P SPECT shows promise as an objective measure to assess lung ventilation and perfusion to observe and assess responsiveness to mepolizumab. With quantification, this measure may allow better precision in determining treatment improvements.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Mepolizumab, severe asthma, treatable traits, V-P SPECT, ventilation
in
Respirology Case Reports
volume
9
issue
3
article number
e00717
publisher
Wiley-Blackwell
external identifiers
  • pmid:33552524
  • scopus:85101249962
ISSN
2051-3380
DOI
10.1002/rcr2.717
language
English
LU publication?
no
id
d6bc1f11-de1e-4338-9fa0-394fc8f0c836
date added to LUP
2021-03-09 10:45:47
date last changed
2024-06-13 08:07:43
@article{d6bc1f11-de1e-4338-9fa0-394fc8f0c836,
  abstract     = {{<p>Monoclonal antibody therapies are effective for many but not all people with severe asthma. Precision medicine guides treatment selection using biomarkers to select patients most likely to respond according to their inflammatory endotypes. However, when assessing response to treatment, greater precision is required. We report a case series describing treatment response to mepolizumab in four severe asthma patients, assessed by traditional methods and with objective ventilation/perfusion single photon emission computed tomography (V-P SPECT). In this series, patients with severe asthma received mepolizumab treatment with clinical outcomes recorded at commencement and at approximately 16 weeks post-treatment initiation. V-P SPECT imaging was performed before and after treatment to determine ventilation heterogeneity and perfusion, and its ability to assess treatment responsiveness. V-P SPECT shows promise as an objective measure to assess lung ventilation and perfusion to observe and assess responsiveness to mepolizumab. With quantification, this measure may allow better precision in determining treatment improvements.</p>}},
  author       = {{McDonald, Vanessa M. and Urroz, Paola D. and Bajc, Marika and Rutherford, Natalie and Brooker, Bree and Gibson, Peter G.}},
  issn         = {{2051-3380}},
  keywords     = {{Mepolizumab; severe asthma; treatable traits; V-P SPECT; ventilation}},
  language     = {{eng}},
  number       = {{3}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Respirology Case Reports}},
  title        = {{Imaging for precision medicine : can V-P SPECT measure mepolizumab response in asthma?}},
  url          = {{http://dx.doi.org/10.1002/rcr2.717}},
  doi          = {{10.1002/rcr2.717}},
  volume       = {{9}},
  year         = {{2021}},
}